SFM
ZYNE

Sphera Funds Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Sphera Funds Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-100,000
Closed -$383K – 112
2020
Q1 		$383K Buy
+100,000
New +$465K 0.05% 71
2017
Q2 		– Sell
-100,000
Closed -$2.01M – 141
2017
Q1 		$2.01M Buy
+100,000
New +$1.99M 0.39% 70

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sphera Funds Management's ZYNE Position: Q2 2020 in Review

Sphera Funds Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2020, closing a stake of 100,000 shares — an estimated $383K sold.

Sphera Funds Management first reported a position in ZYNE in Q1 2017 and held it in 2 quarters. The position peaked at $2.01M in Q1 2017. 74 funds tracked by Wall St. Rank hold ZYNE as of Q2 2020.

  • Sphera Funds Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2020 after selling out during the quarter.
  • Sphera Funds Management sold 100,000 Zynerba Pharmaceuticals, Inc shares in Q2 2020, an estimated $383K.
  • Sphera Funds Management first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2017 and held it in 2 quarters.
  • Sphera Funds Management's Zynerba Pharmaceuticals, Inc position peaked at $2.01M in Q1 2017.
  • 74 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2020.

Based on Sphera Funds Management's 13F filing for Q2 2020, filed 13 Aug 2020.